Markets are under pressure this morning as index futures slide following disappointing corporate news and lingering concerns over the technology sector. Oracle’s shares are sharply lower after a downbeat forecast and heavy capital spending tied to its AI business. This drag on tech names like Nvidia, Microsoft, Broadcom and other AI-linked equities has knocked futures lower and put a cooler tone on the market.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Globally, markets are mixed. Some Gulf markets are holding modest gains in response to the Fed easing, while Asian and European tech-heavy indices have softened in the wake of the tech selloff. Currency and bond markets are also reacting to the Fed’s messaging and macro dynamics.
In pre-market trading, S&P 500 futures fell 0.4%, Nasdaq futures fell 0.62% and Dow futures were flat.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Gemini (GEMI) up 9% after receiving a designated contract market license from the Commodity Futures Trading Commission, which will allow Gemini to begin offering prediction markets to U.S. customers
- Corbus Pharmaceuticals (CRBP) up 8% after completing the single ascending dose and multiple ascending dose Phase 1a study of CRB-913
- Eli Lilly (LLY) up 1% after reporting each dose of retatrutide met all primary and key secondary endpoints in its TRIUMPH-4 clinical trial
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
- Oracle (ORCL) down 13%
- Oxford Industries (OXM) down 21%
- Lovesac (LOVE) down 16%
- Hooker Furniture (HOFT) down 14%
- Manchester United (MANU) down 2%
- Vera Bradley (VRA) down 1%
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY and NOVO: Goldman Sachs Weighs In on the Top Obesity Stocks to Watch in 2026
- Eli Lilly reports TRIUMPH-4 trial of retatrutide met primary endpoint
- Eli Lilly’s Strategic Advancements in Incretin Pipeline and Diversification Drive Buy Rating
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Mixed options sentiment in Eli Lilly with shares up 0.67%